Adaptimmune Therapeutics PLC — Director's Dealing 2019

Jan 9, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2019-01-04

Reporting Person: Noble James (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-04	Option to purchase Ordinary Shares	$0.89	A	2515536	Acquired	2029-01-04	Ordinary Shares (2515536)	Direct
2019-01-04	Option to purchase Ordinary Shares	$0.0013	A	561792	Acquired	2029-01-04	Ordinary Shares (561792)	Direct

Footnotes

F1: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 628,884 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 52,404 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 52,512 Ordinary Shares on January 4, 2023.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 140,448 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 140,448 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023.